Interventional cardiology is a branch of cardiology that deals with catheter based treatment for heart diseases. By catheterization, number of procedures can be performed on the heart. According to International Diabetes Federation, 60% of world’s total diabetic population lives in Asia. Diabetic is one of the major factors which lead to cardiovascular diseases. Increasing prevalence of cardiovascular diseases is the major factor for the growth of the market in Asia Pacific. Beside this increasing incidences of diabetes and obesity, change in lifestyle, increasing awareness among the people and rapid development in technology also contributed to the growth of the market. On other hand, high cost for manufacturing the devices and lot of barriers for the development of the new device are the major restraints hampering the market growth.
Asia Pacific interventional cardiology market is expected to grow at a CAGR of 7.9% during the forecasted period 2017-2023.
Segmentation
Asia Pacific interventional cardiology market is segmented on the basis of type, into catheters, stents, balloons, vascular closure devices, laser procedures, atherectomy and other. Stents are sub segmented into metal stents, drug eluting stents and bioresorbable stents. Balloons are further segmented into cutting balloons, drug eluting balloons and other. On the basis of end users the market is segmented into catheterization laboratories, hospitals and clinics and others
Key Players for Asia Pacific interventional cardiology market
Abbott Laboratories Inc. (U.S.), B. Braun Melsungen AG (Germany), C.R. Bard, Inc. (U.S.), Abiomed Inc. (U.S), Edwards Lifesciences (U.S.), Biosensors International Group, Ltd. ( Singapore), Boston Scientific Corporation (U.S.), Medtronic PLC (Ireland), Angiodynamics, Inc. ( U.S), Terumo Medical Corporation (Japan), Johnson & Johnson Services, Inc. (U.S.)., Lombard Medical Technologies, Plc. (U.K), Clearstream Technologies Group Plc. (Ireland).